Page 4 - Flipbook

Learning Objectives

At the conclusion of this program, participants will be able to:

• Describe the significance and appropriate timing for testing

for germline and somatic mutations in mCRPC

• Evaluate the different modalities and avenues for testing

• Review clinical safety and efficacy data for PARP inhibitors

• Discuss the rationale for PARP inhibitor utilization in HRR-

mutated mCRPC